Famta Paras, Shah Saurabh, Chatterjee Essha, Singh Hoshiyar, Dey Biswajit, Guru Santosh Kumar, Singh Shashi Bala, Srivastava Saurabh
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Department of Pharmacology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Curr Res Pharmacol Drug Discov. 2021 Sep 6;2:100054. doi: 10.1016/j.crphar.2021.100054. eCollection 2021.
The high probability (13%) of women developing breast cancer in their lifetimes in America is exacerbated by the emergence of multidrug resistance after exposure to first-line chemotherapeutic agents. Permeation glycoprotein (P-gp)-mediated drug efflux is widely recognized as the major driver of this resistance. Initial and investigations of the co-delivery of chemotherapeutic agents and P-gp inhibitors have yielded satisfactory results; however, these results have not translated to clinical settings. The systemic delivery of multiple agents causes adverse effects and drug-drug interactions, and diminishes patient compliance. Nanocarrier-based site-specific delivery has recently gained substantial attention among researchers for its promise in circumventing the pitfalls associated with conventional therapy. In this review article, we focus on nanocarrier-based co-delivery approaches encompassing a wide range of P-gp inhibitors along with chemotherapeutic agents. We discuss the contributions of active targeting and stimuli responsive systems in imparting site-specific cytotoxicity and reducing both the dose and adverse effects.
在美国，女性一生中患乳腺癌的概率很高（13%），而在接触一线化疗药物后出现多药耐药性，这一情况更加严重。通透糖蛋白（P-gp）介导的药物外排被广泛认为是这种耐药性的主要驱动因素。对化疗药物和P-gp抑制剂共递送的初步研究取得了令人满意的结果；然而，这些结果尚未转化到临床应用中。多种药物的全身递送会产生副作用和药物相互作用，并降低患者的依从性。基于纳米载体的位点特异性递送最近在研究人员中受到了广泛关注，因为它有望规避传统治疗的缺陷。在这篇综述文章中，我们重点关注基于纳米载体的共递送方法，这些方法涵盖了广泛的P-gp抑制剂以及化疗药物。我们讨论了主动靶向和刺激响应系统在赋予位点特异性细胞毒性以及降低剂量和副作用方面的作用。
